

REMARKS

Claims 1-38 are now pending in the application. Claims 1-38 are subject to restriction. Claims 1-38 are canceled and claims 39-57 are added herein. New claims 39-57 are believed to fall under the asserted Group IV as they are directed to polynucleotides encoding SGP28 polypeptides or fragments thereof. Support for the new claims can be found throughout the specification and claims as originally filed. No new matter has been added.

Applicants expressly reserve their right under 35 U.S.C. § 121 to file a divisional application directed to the nonelected subject matter during the pendency of this application, or an application claiming priority from this application.

In the unlikely event that the Patent Office determines that extensions and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or fees due to our Deposit Account No. 03-1952 under Order No. 511582002300. The Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: August 30, 2002

By:



David L. Devernøe
Registration No. 50,128

Morrison & Foerster LLP
3811 Valley Centre Drive,
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7943
Facsimile: (858) 720-5125